Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®
NCT01294020
Heart Transplantation, Intestine Transplantation
Brussels, Belgium
View Trial DetailsNCT Number: NCT00531921
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection. The purpose of this study is to determine the relationship between genetic expression in donor and recipient tissue with transplant survival. Participants in this study will have received heart, lung, liver, or kidney transplants.
Looking for future studies?
Notify MeUp to 70 year
All sexes
Observational
Northwestern Memorial Hospital (kidney and liver), Chicago, Illinois, United States
Inflammation and injuries to transplanted organs during the immediate post-operative period may be linked to early organ dysfunction and higher rates of transplant rejection in the recipient. Currently, mRNA expression of proinflammatory genes in donor tissues is thought to be a risk factor for early organ transplant dysfunction, increased expression of the recipients cell-mediated immunity genes, and organ rejection. The purpose of this study is to test the association between proinflammatory mRNA expression in donor samples and subsequent development of early organ dysfunction in kidney, lung, and liver transplant recipients. This study will also test the effects of proinflammatory mediators expressed in the transplanted organ pre- and post-reperfusion on organ rejection and genes expressed in cell mediated immune responses. This will be achieved by identifying the proinflammatory immune responses and their mechanisms.
This study will consist of up to 11 study visits over a period of 2 years. The baseline visit will occur 24 hours prior to organ transplantation. Follow-up visits will occur daily for Days 1 to 3 (for lung transplant recipients only) and on Day 7, Week 6, and Months 3, 6, 9, 12, 18, and 24 post-transplant. At the baseline visit, a physical exam, medical history, demographics, vital signs measurements, blood collection, and collection of donor tissue sample will occur. For most or all other study visits, medication and adverse events tracking and blood collection will occur. Depending on the transplant type, participants will undergo the following procedures:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for all participants:
Inclusion criteria
for Kidney or Liver Transplant Participants:
Inclusion criteria
for Heart or Lung Transplant Participants:
Exclusion criteria
for All Participants:
Time frame: Within first 7 days after transplant
Time frame: 12 months after transplant
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
Correlation of Donor Proinflammatory mRNA Profiles With Early Outcomes of Thoracic and Abdominal Transplantation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01294020
Heart Transplantation, Intestine Transplantation
Brussels, Belgium
View Trial DetailsNCT00209196
Heart Transplantation, Heart-Lung Transplantation
Atlanta, Georgia, United States
View Trial DetailsNCT06341543
Cytomegalovirus Infections, DNA Virus Infections
Grenoble, Maryland, France
View Trial DetailsNCT02118896
Heart Transplantation, Kidney Transplantation
Cincinnati, Ohio, United States
View Trial Details